


# SEEING IS BELIEVING™

## THE IMPORTANCE OF TESTING FOR HPV

- HPV is the primary cause of cervical cancer.<sup>1</sup>
- HPV testing for ASC-US Paps identifies patients who require colposcopy and immediate follow-up vs. those who do not.<sup>2</sup>
- There are approximately 2 million ASC-US Paps reported in the U.S. annually.<sup>3</sup>
- Only a small percentage of ASC-US Paps progress to cancer.<sup>4</sup>

### Proposed Algorithm for the Triage of Women with ASC-US Papanicolaou Test Results<sup>3</sup>



## ADVANTAGES OF SLIDE-BASED MOLECULAR HPV TESTING

- Detection of HPV DNA in both tissue and LBP.
- Sensitivity is 10-20 copies of target DNA per nucleus.<sup>5</sup>
- Type of signal, confluent or punctuate, may reflect either episomal or integrated virus.
- Allow direct correlation of the HPV DNA results with the cytology.
- Simultaneous reporting of both results, HPV and Cytology, as recommended by Bethesda 2001.<sup>6</sup>

## ADVANTAGES OF INFORM® HPV SLIDE BASED *in situ* HYBRIDIZATION

- Fully automated by Ventana Medical Systems, Inc. on the BenchMark™ Automated Slide Staining System.
- The sensitivity, specificity, and positive predictive value (PPV) is superior to HCII.<sup>7</sup>
- Negative predictive value (NPV) was equivalent to HCII.<sup>7</sup>

### References

1. Franco, E.L., Epidemiology Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer.1999; 91(6): 506-511.
2. Bosch, F.X., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
3. Manos, M.M., Identifying Women with Cervical Neoplasia: Using Human Papillomavirus DNA Testing for Equivocal Papanicolaou Results. JAMA 1999; 281 1605-1610.
4. The Atypical Squamous Cells of Undetermined Significance/Low Grade Squamous Intraepithelial Lesions Triage Study (ALTS) J Natl Ins 2000; 92:394-402.
5. Nuovo, G.J. The Role of Human Papillomavirus in Gynecologic Disease, Advances in Pathology and Laboratory Medicine, 8:119-147, 1995.
6. Wright, T.C., 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities, JAMA 2002; 287:2120-2129.
7. Qureshi, M.N. Predicting Cervical Lesions by INFORM® HPV and Hybrid Capture II® Platform Presentation in Section G-Abstract #334 USCAP 2003. Modern Pathology, 2003 16;1:78A

Reference available upon request: 1-800-227-2155

